Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 26, 2003. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific share transactions and does not contain financial performance data.
Material Changes
The primary material change reported is a transaction involving the GlaxoSmithKline Employee Trust ("the GSK Trust"). On September 24, 2003, the GSK Trust transferred 17,426 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The company was advised of this transaction on September 25, 2003.
Management Commentary and Risks
The filing notes that the GSK Trust is a discretionary trust where all employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Consequently, directors Dr. J-P Garnier and Mr. J D Coombe are interested in the shares held in the GSK Trust in the same manner as other employees. No other risks, contingencies, or unusual items are disclosed in this text.
Key Facts for Investors
- The filing reports a transfer of 17,426 Ordinary Shares from the GSK Trust to employee plan participants.
- Directors Dr. J-P Garnier and Mr. J D Coombe hold indirect interests in the GSK Trust shares alongside other employees.
- This document contains no financial performance metrics or forward-looking guidance.